Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Sharecast News) - AstraZeneca announced on Thursday that the phase 3 'TULIP 2' trial for 'anifrolumab' - a potential new medicine for the treatment of systemic lupus erythematosus (SLE) - met its primary endpoint, achieving a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo, with both arms receiving standard of care.
29 Aug 19 07:29(Sharecast News) - Greggs: UBS upgrades to buy with a target price of 2,300p.
28 Aug 19 12:43(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------BP, up
28 Aug 19 10:37(Alliance News) - AstraZeneca PLC on Wednesday posted positive results from its phase three trial of Breztri Aerosphere and said Fasenra has been granted orphan drug designation in the phase 3 of
28 Aug 19 08:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
28 Aug 19 07:38(Alliance News) - AstraZeneca PLC on Tuesday said the US has granted fast track designation for the development of Farixga as a treatment for renal failure in chronic kidney disease.The US
27 Aug 19 08:50(Alliance News) - AstraZeneca PLC announced Chinese approval for roxadustat in non-dialysis-dependent patients on Thursday, as well as the USD95 million purchase of a priority review voucher in Co
22 Aug 19 08:36
Last checked at